CA3124996A1 - Il-36r antibodies for treatment of palmoplantar pustulosis - Google Patents

Il-36r antibodies for treatment of palmoplantar pustulosis Download PDF

Info

Publication number
CA3124996A1
CA3124996A1 CA3124996A CA3124996A CA3124996A1 CA 3124996 A1 CA3124996 A1 CA 3124996A1 CA 3124996 A CA3124996 A CA 3124996A CA 3124996 A CA3124996 A CA 3124996A CA 3124996 A1 CA3124996 A1 CA 3124996A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
weeks
ppp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124996A
Other languages
English (en)
French (fr)
Inventor
Christian Thoma
Patrick BAUM
Janine LAMAR
Steven John PADULA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA3124996A1 publication Critical patent/CA3124996A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3124996A 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis Pending CA3124996A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US62/785,316 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US62/815,431 2019-03-08
US201962891464P 2019-08-26 2019-08-26
US62/891,464 2019-08-26
PCT/EP2019/086521 WO2020136101A1 (en) 2018-12-27 2019-12-20 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3265173A Division CA3265173A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Publications (1)

Publication Number Publication Date
CA3124996A1 true CA3124996A1 (en) 2020-07-02

Family

ID=69190739

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124996A Pending CA3124996A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Country Status (14)

Country Link
US (3) US20200207862A1 (enExample)
EP (1) EP3902604A1 (enExample)
JP (1) JP2022515480A (enExample)
KR (1) KR20210119407A (enExample)
CN (1) CN113301955A (enExample)
AU (1) AU2019416727A1 (enExample)
BR (1) BR112021010789A2 (enExample)
CA (1) CA3124996A1 (enExample)
CL (1) CL2021001685A1 (enExample)
IL (1) IL284259A (enExample)
MX (1) MX2021007807A (enExample)
PH (1) PH12021551540A1 (enExample)
TW (1) TW202037604A (enExample)
WO (1) WO2020136101A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
BR112022026999A2 (pt) * 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
EP4221839A1 (en) * 2020-09-30 2023-08-09 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
EP4334356A1 (en) * 2021-05-03 2024-03-13 Boehringer Ingelheim International Gmbh Method for producing spesolimab
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
EP4370550A1 (en) * 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2024138141A2 (en) * 2022-12-23 2024-06-27 Icosavax, Inc. Antibodies against metapneumovirus fusion (f) protein and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
CN112870489B (zh) 2015-04-24 2022-12-06 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
BR112020016738A2 (pt) * 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada

Also Published As

Publication number Publication date
CN113301955A (zh) 2021-08-24
PH12021551540A1 (en) 2022-02-21
EP3902604A1 (en) 2021-11-03
US20230131364A1 (en) 2023-04-27
TW202037604A (zh) 2020-10-16
AU2019416727A1 (en) 2021-07-22
US20230115617A1 (en) 2023-04-13
JP2022515480A (ja) 2022-02-18
IL284259A (en) 2021-08-31
CL2021001685A1 (es) 2022-02-18
US20200207862A1 (en) 2020-07-02
WO2020136101A1 (en) 2020-07-02
KR20210119407A (ko) 2021-10-05
MX2021007807A (es) 2021-08-11
BR112021010789A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
US20230131364A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
JP7673168B2 (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
TW202346344A (zh) 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
CA3209006A1 (en) Methods for the treatment of gpp
US20220010022A1 (en) Anti-il-36r antibodies for the treatment of atopic dermatitis
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
KR20230004489A (ko) 아토피 피부염 및 관련 장애의 치료 방법
AU2014259526B2 (en) Methods of treating ankylosing spondylitis using IL-17 antagonists
EA046186B1 (ru) Применение антител к il-36r для лечения генерализованного пустулёзного псориаза
HK40083901A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies